双鹭药业
(002038)
| 流通市值：48.15亿 | | | 总市值：58.05亿 |
| 流通股本：8.52亿 | | | 总股本：10.27亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 251,479,393.18 | 136,840,808.89 | 623,643,928.9 | 458,752,567.68 |
| 营业总成本 | 248,722,029.09 | 102,494,124.4 | 628,880,940.37 | 442,623,429.84 |
| 其他经营收益 | | | | |
| 营业利润 | -302,906,949.5 | -103,788,074.16 | -279,285,559.45 | 162,030,693.89 |
| 利润总额 | -297,476,719.23 | -103,792,548.61 | -278,144,237.45 | 158,859,722.02 |
| 净利润 | -255,807,233.58 | -87,268,289.74 | -348,208,492.02 | 140,630,600.69 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | -35,241,507.99 | - |
| 综合收益总额 | -255,807,233.58 | -87,268,289.74 | -383,450,000.01 | 140,630,600.69 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,571,073,035.57 | 2,048,877,844.28 | 2,093,962,255.15 | 2,586,400,343.39 |
| 非流动资产: | | | | |
| 非流动资产合计 | 3,703,396,778.14 | 3,787,900,515.6 | 3,978,116,310.92 | 3,442,287,794.94 |
| 资产总计 | 5,274,469,813.71 | 5,836,778,359.88 | 6,072,078,566.07 | 6,028,688,138.33 |
| 流动负债: | | | | |
| 流动负债合计 | 201,912,348.5 | 605,362,727.39 | 729,587,235.38 | 209,038,655.29 |
| 非流动负债: | | | | |
| 非流动负债合计 | 139,779,459.43 | 130,098,682.87 | 153,906,091.33 | 118,917,642.97 |
| 负债合计 | 341,691,807.93 | 735,461,410.26 | 883,493,326.71 | 327,956,298.26 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 4,926,320,386.33 | 5,095,281,191.64 | 5,181,395,631.4 | 5,692,998,987.18 |
| 股东权益合计 | 4,932,778,005.78 | 5,101,316,949.62 | 5,188,585,239.36 | 5,700,731,840.07 |
| 负债和股东权益合计 | 5,274,469,813.71 | 5,836,778,359.88 | 6,072,078,566.07 | 6,028,688,138.33 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 533,000,796.78 | 236,834,409.33 | 1,337,820,665.03 | 1,166,739,406.02 |
| 经营活动现金流出小计 | 304,655,955.88 | 178,178,727.68 | 1,080,157,395.9 | 1,172,571,144.32 |
| 经营活动产生的现金流量净额 | 228,344,840.9 | 58,655,681.65 | 257,663,269.13 | -5,831,738.3 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 499,003,983.93 | 132,359,242.7 | 366,100,719.41 | 274,553,591.71 |
| 投资活动现金流出小计 | 465,271,764.48 | 106,378,662.71 | 505,381,370 | 285,025,786.75 |
| 投资活动产生的现金流量净额 | 33,732,219.45 | 25,980,579.99 | -139,280,650.59 | -10,472,195.04 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | 50,000,000 | - | - |
| 筹资活动现金流出小计 | - | - | 17,895,318.86 | 20,547,000 |
| 筹资活动产生的现金流量净额 | - | 50,000,000 | -17,895,318.86 | -20,547,000 |
| 汇率变动对现金及现金等价物的影响 | -16.73 | -9.67 | 6.73 | 11.44 |
| 现金及现金等价物净增加额 | 262,077,043.62 | 134,636,251.97 | 100,487,306.41 | -36,850,921.9 |
| 期末现金及现金等价物余额 | 762,442,599 | 635,001,807.35 | 500,365,555.38 | 363,027,327.07 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 262,077,043.62 | - | 100,487,306.41 | - |